<PAGE>

                                                            EXHIBIT 10.2


                         AMENDMENT TO LICENSE AGREEMENT


    This Amendment to License Agreement ("Amendment") is entered into as of 
August 26, 1997, by and between Avid Corporation, a Pennsylvania corporation 
("Licensee"), and The DuPont Merck Pharmaceutical Company, a Delaware general 
partnership ("Licensor"), and amends certain terms of that certain License 
Agreement dated December 18, 1996, between Licensee and Licensor (the 
"Agreement").  Capitalized terms not defined herein shall have the meanings 
given to them in the Agreement.

                                    RECITALS

    A.   Licensee and Licensor have previously entered into the Agreement, 
pursuant to which Licensor has licensed certain technology to Licensee.

    B.   Licensee and Licensor desire to amend certain terms of the Agreement 
as set forth in this Amendment.

    NOW, THEREFORE, for good and valuable consideration, Licensee and 
Licensor hereby agree as follows:

    1.   AMENDMENTS.  The Agreement is hereby amended as follows:

         a.   SECTION 1.10.  In Section 1.10, the words "bismethanesulfonic 
acid salt" in the fourth and fifth lines are hereby deleted, and the words 
"and all salts thereof, and all esters of the vicinal dihydroxy group and all 
salts thereof" are hereby inserted after the word "3-diazepin-2-one," in the 
fourth line.

         b.   SECTION 3.05.  In Section 3.05, the first two sentences are 
hereby deleted, and the following sentences are hereby added to the beginning 
of Section 3.05: "Licensee has the right to sublicense the rights granted it 
pursuant to this Agreement to any unrelated, unaffiliated third party after 
obtaining Licensor's prior written consent.  Licensor agrees to consider any 
request for consent to sublicense in good faith and shall not unreasonably 
withhold or delay such consent.  In the event Licensee sublicenses the rights 
granted it hereunder to any unrelated, unaffiliated third party, then 
Licensee shall pay Licensor      ***       of the cash equivalent of any 
license fee and technology premium equity payment that Licensee receives it 
from its Sublicensee ("Additional Payment").


*** Portions of this page have been omitted pursuant to a request for 
    Confidential Treatment and filed separately with the commission.

<PAGE>

         c.   SECTION 6.01:    In Section 6.01, insert the subsection 
designation "(i)" after the section heading and before the first sentence and 
add the following sentences as a new Section 6.01 (ii):

         "(ii) Licensor shall reasonably cooperate with Licensee and shall 
         provide Licensee with copies of material filings and correspondence 
         pertaining to the prosecution and maintenance of the Patent Rights 
         ("Patent Prosecution Activities") and give Licensee an opportunity to 
         comment thereon.  Licensor shall consider requests made by Licensee to 
         pursue Patent Prosecution Activities, and shall make a good faith 
         determination of whether to pursue such Patent Prosecution Activities. 
         Licensor shall provide notice to Licensee of any decision by Licensor 
         to discontinue or to not pursue Patent Prosecution Activities in a 
         particular country promptly upon reaching such decision and, in the 
         case of a decision to discontinue Patent Prosecution Activities, no 
         less than       ***     before the discontinuance thereof.  Upon 
         receipt of such notice, or in the event that Licensor fails to timely 
         pursue Patent Prosecution Activities, Licensee shall be free at its 
         own expense, to pursue, continue or discontinue any or all of the 
         Patent Prosecution Activities in that particular country.  Upon the 
         request of Licensee, Licensor shall consider in good faith filing for 
         reissue patents with claims specifically directed to the Licensed 
         Compound and methods for its therapeutic use.  Notwithstanding 
         anything to the contrary, failure by Licensor to perform any of its 
         obligations described in this Section 6.01 (ii) shall not be 
         considered a breach of this Agreement."

         d.   SECTION 11.03.  Section 11.03 is hereby amended in its entirety 
to read as follows:

    "Both Licensor and Licensee may freely transfer or assign their rights and 
    obligations under this Agreement to any Affiliate without the prior consent 
    of the other party.  Licensee may not assign its rights and obligations 
    under this Agreement to any unrelated, unaffiliated third party without the 
    prior written consent of Licensor and any attempted assignment without such 
    consent shall be void.  Licensor agrees to consider any request for such an 
    assignment in good faith and shall not unreasonably withhold or delay its 
    consent thereto.  As a condition to any transfer or assignment, the 
    transferee must agree to be bound by the obligations of the transferor. 
    Subject to the foregoing, this Agreement shall bind and inure to the 
    benefit of the parties and their respective successors and assigns." 

         e.   SCHEDULE B.  Schedule B is hereby amended in its entirety and 
replaced with Schedule B in the form attached to this Amendment.


*** Portions of this page have been omitted pursuant to a request for 
    Confidential Treatment and filed separately with the commission.

<PAGE>

    2.   ACKNOWLEDGEMENT.  Licensor hereby acknowledges that, as of the date 
hereof, Licensee has substantially complied with the Development Schedule and 
has satisfied its         ***      under Section 5.01 of the Agreement.

    3.   GENERAL TERMS.  The Agreement, as amended by this Amendment, 
constitutes the entire agreement between Licensee and Licensor regarding the 
subject matters contained therein and herein.  In the event of any conflict 
between the provisions of the Agreement and this Amendment, the provisions of 
this Amendment shall govern and control.  This Amendment shall be governed 
by, and construed in accordance with, the laws of the      ***      without 
regard to its conflicts of laws principles.  This Amendment may be executed 
in any number of counterparts, each of which shall be deemed an original and 
all of which shall constitute one and the same instrument.  If any provision 
of this Amendment is for any reason held to be ineffective, unenforceable or 
illegal, such condition shall not affect the validity or enforceability of 
any of the remaining portions hereof-, provided, further, that the parties 
shall negotiate in good faith to replace any ineffective, unenforceable or 
illegal provision with an effective replacement as soon as is practical.

    IN WITNESS WHEREOF, Licensee and Licensor have each executed this 
Amendment through an authorized officer as of the date written below.

                                   AVID CORPORATION


                                   By: /s/  illegible
                                       ---------------------------------------

                                   Its: Executive Vice Pres & General Counsel
                                        --------------------------------------

                                   Date:     August 26, 1997               
                                         -------------------------------------


                                   THE DUPONT MERCK
                                   PHARMACEUTICAL COMPANY


                                   By: /s/  illegible                   
                                       ---------------------------------------

                                   Its: President                      
                                        --------------------------------------
 
                                   Date: August 26, 1997               
                                         -------------------------------------


*** Portions of this page have been omitted pursuant to a request for 
    Confidential Treatment and filed separately with the commission.


<PAGE>

                                   SCHEDULE B



                                      ***
                                      ***
                                      ***
                                      ***


*** Portions of this page have been omitted pursuant to a request for 
    Confidential Treatment and filed separately with the commission.